GH1 and acromegaly: A recent meta-analysis of clinical studies with sustained release octreotide and lanreotide indicated normalization of GH and IGF-1 in 56% and 55%, respectively, of treated patients with acromegaly (Carmichael et al., 2014); however, most of the included studies did not use the current normalization criteria of GH <1% and did not consider composite GH and IGF-1 normalization (Gadelha et al., 2017).